OSE Immunotherapeutics SA(DE:6OP)
€1.650.01 (-1.43%)
DE:6OP
OSE Immunotherapeutics SA financials statements
€1.65
At close:0.01 (-1.43%)
OSE Immunotherapeutics SA (6OP) Ratios
1 Followers
OSE Immunotherapeutics SA Ratios
DE:6OP's free cash flow for Q4 2025 was €-16.14M. For the 2025 fiscal year, DE:6OP's free cash flow was decreased by €-89.00K and operating cash flow was €-16.05M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.28 | 3.46 | 1.62 | 2.29 | 2.64 |
| Quick Ratio | 1.28 | 3.46 | 1.62 | 2.29 | 2.64 |
| Cash Ratio | 0.71 | 0.83 | 0.99 | 1.57 | 2.00 |
| Solvency Ratio | -0.67 | 0.68 | -0.33 | -0.24 | -0.26 |
| Operating Cash Flow Ratio | -1.37 | 2.40 | -1.05 | -1.12 | -0.59 |
| Short-Term Operating Cash Flow Coverage | -3.41 | 6.22 | -3.09 | -5.90 | -6.16 |
| Net Current Asset Value | € -19.11M | € 9.78M | € -28.60M | € -21.92M | € -9.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.45 | 0.37 | 0.56 | 0.49 | 0.37 |
| Debt-to-Equity Ratio | 1.29 | 0.72 | 2.01 | 1.38 | 0.78 |
| Debt-to-Capital Ratio | 0.56 | 0.42 | 0.67 | 0.58 | 0.44 |
| Long-Term Debt-to-Capital Ratio | 0.44 | 0.36 | 0.61 | 0.53 | 0.39 |
| Financial Leverage Ratio | 2.87 | 1.94 | 3.60 | 2.82 | 2.12 |
| Debt Service Coverage Ratio | -3.13 | 3.50 | -1.99 | -1.66 | -3.68 |
| Interest Coverage Ratio | -16.26 | 13.25 | -10.13 | -13.47 | -19.89 |
| Debt to Market Cap | 0.28 | 0.28 | 0.50 | 0.33 | 0.17 |
| Interest Debt Per Share | 1.72 | 2.27 | 2.46 | 2.50 | 2.09 |
| Net Debt to EBITDA | -0.40 | 0.71 | -1.55 | -1.46 | -0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1835.01% | 54.14% | -944.14% | -90.97% | -62.26% |
| EBITDA Margin | -1711.00% | 58.95% | -785.86% | -71.65% | -52.16% |
| Operating Profit Margin | -1835.01% | 62.59% | -1032.15% | -100.95% | -63.20% |
| Pretax Profit Margin | -1605.73% | 57.00% | -1042.75% | -128.15% | -81.95% |
| Net Profit Margin | -1439.48% | 53.59% | -1032.91% | -97.04% | -64.05% |
| Continuous Operations Profit Margin | -1439.06% | 53.59% | -1032.91% | -97.04% | -64.05% |
| Net Income Per EBT | 89.65% | 94.01% | 99.06% | 75.72% | 78.16% |
| EBT Per EBIT | 87.50% | 91.08% | 101.03% | 126.94% | 129.67% |
| Return on Assets (ROA) | -48.06% | 30.21% | -28.03% | -19.37% | -16.60% |
| Return on Equity (ROE) | -137.87% | 58.68% | -100.80% | -54.57% | -35.18% |
| Return on Capital Employed (ROCE) | -89.75% | 42.16% | -36.34% | -24.50% | -19.61% |
| Return on Invested Capital (ROIC) | -67.00% | 36.67% | -32.29% | -17.63% | -14.91% |
| Return on Tangible Assets | -102.17% | 46.84% | -64.52% | -41.41% | -33.43% |
| Earnings Yield | -32.82% | 23.95% | -27.47% | -14.42% | -9.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.37 | 16.89 | 1.23 | 2.25 | 16.50 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.71 | 20.40 | 0.55 | 3.68 | 4.84 |
| Asset Turnover | 0.03 | 0.56 | 0.03 | 0.20 | 0.26 |
| Working Capital Turnover Ratio | 0.09 | 2.28 | 0.14 | 0.76 | 0.99 |
| Cash Conversion Cycle | 986.71 | 21.61 | 295.84 | 162.10 | 22.12 |
| Days of Sales Outstanding | 986.71 | 21.61 | 295.84 | 162.10 | 22.12 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 986.71 | 21.61 | 295.84 | 162.10 | 22.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.53 | 2.22 | -1.01 | -0.99 | -0.55 |
| Free Cash Flow Per Share | -1.53 | 2.22 | -1.02 | -1.00 | -0.57 |
| Dividend Paid and CapEx Coverage Ratio | -347.29 | 629.09 | -85.19 | -66.61 | -21.01 |
| Capital Expenditure Coverage Ratio | -347.29 | 629.09 | -85.19 | -66.61 | -21.01 |
| Operating Cash Flow Coverage Ratio | -0.96 | 1.05 | -0.43 | -0.41 | -0.27 |
| Operating Cash Flow to Sales Ratio | -13.00 | 0.69 | -8.87 | -1.00 | -0.38 |
| Free Cash Flow Yield | -29.71% | 30.93% | -23.88% | -15.04% | -5.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.05 | 4.17 | -3.64 | -6.94 | -11.08 |
| Price-to-Sales (P/S) Ratio | 43.87 | 2.24 | 37.60 | 6.73 | 7.09 |
| Price-to-Book (P/B) Ratio | 4.20 | 2.45 | 3.67 | 3.79 | 3.90 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.37 | 3.23 | -4.19 | -6.65 | -17.96 |
| Price-to-Operating Cash Flow Ratio | -3.38 | 3.23 | -4.24 | -6.75 | -18.82 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.02 | -0.16 | -2.15 | 0.90 |
| Enterprise Value Multiple | -2.96 | 4.51 | -6.33 | -10.86 | -13.86 |
| Enterprise Value | 132.71M | 185.75M | 110.86M | 142.37M | 190.19M |
| EV to EBITDA | -2.96 | 4.51 | -6.33 | -10.86 | -13.86 |
| EV to Sales | 50.67 | 2.66 | 49.78 | 7.78 | 7.23 |
| EV to Free Cash Flow | -3.89 | 3.84 | -5.54 | -7.69 | -18.30 |
| EV to Operating Cash Flow | -3.90 | 3.83 | -5.61 | -7.80 | -19.17 |
| Tangible Book Value Per Share | -0.64 | 0.91 | -1.20 | -0.88 | -0.20 |
| Shareholders’ Equity Per Share | 1.23 | 2.93 | 1.17 | 1.76 | 2.64 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.10 | 0.06 | 0.01 | 0.24 | 0.22 |
| Revenue Per Share | 0.12 | 3.20 | 0.11 | 0.99 | 1.45 |
| Net Income Per Share | -1.69 | 1.72 | -1.18 | -0.96 | -0.93 |
| Tax Burden | 0.90 | 0.94 | 0.99 | 0.76 | 0.78 |
| Interest Burden | 0.88 | 1.05 | 1.10 | 1.41 | 1.32 |
| Research & Development to Revenue | 12.94 | 0.47 | 7.70 | 1.47 | 1.16 |
| SG&A to Revenue | 2.12 | 0.12 | 2.68 | 0.36 | 0.32 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.78 | 0.15 | 0.14 |
| Income Quality | 0.90 | 1.29 | 0.86 | 1.03 | 0.59 |
Currency in EUR
